Find Clinical Drug Pipeline Developments & Deals for Rhenium-186

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rhenium-186

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Plus Therapeutics

            Deal Size: $137.2 million Upfront Cash: $0.4 million

            Deal Type: Licensing Agreement May 11, 2020

            Details:

            Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.